Case NF1 or Sporadic Histology Age at tumor diagnosis (years) Age at BBT (years) Posterior extent of tumor BBT Indication BBT F/u (mo)* VA VF Radiographic Outcome
Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6 Patients with vision decline as indication for BBT, N = 6
1 Sporadic JPA 10.3 10.7 Post-chiasmatic R + V BEV/CPT 5 Worse Worse Stable
2 Sporadic No biopsy 8.8 9.7 Optic nerve R + V BEV/CPT 32 Better Stable Stable
3 Sporadic JPA 13.2 16.5 Post-chiasmatic R + V BEV/CPT 13 Stable Better Progression
4 Sporadic JPA 6.6 9.1 Chiasm V BEV/CPT 32 Stable Stable Stable
5 NF1 JPA 4.8 16.1 Post-chiasmatic R + V BEV/CPT 21 Stable Better Progression
6 NF1 No biopsy 7.7 7.9 Post-chiasmatic V BEV 14 Stable Better Progression
Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11 Patients with radiographic progression alone as indication for BBT, N = 11
7 NF1 JPA 12.5 17.6 Post-chiasmatic R BEV/VBL 17 Stable Worse Progression
8 Sporadic JPA 11.1 12.8 Post-chiasmatic R BEV 8 Stable Worse Stable
9 Sporadic PXA 5.8 6.9 Post-chiasmatic R BEV/CPT 15 Stable Stable Stable
10 Sporadic JPA 1.0 2.7 Post-chiasmatic R BEV/CPT 12 Better NA Stable
11 Sporadic JPA 2.6 14.3 Post-chiasmatic R BEV 6 Stable NA Progression
12 Sporadic PXA 0.5 3.0 Post-chiasmatic R BEV/CPT 11 Stable NA Progression
13 Sporadic No biopsy 0.9 3.5 Post-chiasmatic R BEV/CPT 11 Better NA Stable
14 Sporadic JPA 5.6 7.4 Post-chiasmatic R BEV/CPT 20 Stable NA Stable
15 Sporadic PXA 3.1 3.7 Post-chiasmatic R BEV/CPT 13 Stable NA Progression
16 Sporadic JPA 1.3 3.8 Chiasm R BEV/CPT 12 Worse NA Stable
17 Sporadic PXA 3.9 4.9 Post-chiasmatic R BEV/CPT 13 Worse NA Progression
*Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data *Follow-up time from treatment start to last vision assessment; †Visual acuity (VA) and visual field (VF) assessments at last follow-up or at progression Abbreviations: NF1, neurofibromatosis type 1; JPA, juvenile pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; BBT, bevacizumab-based therapy; R, radiographic progression; V, vision decline; BEV, bevacizumab; CPT, irinotecan, VBL, vinblastine; NA, no data